Sitravatinib
- Generic Name
- Sitravatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C33H29F2N5O4S
- CAS Number
- 1123837-84-2
- Unique Ingredient Identifier
- CWG62Q1VTB
- Background
Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Phase 3
- Conditions
- Advanced Malignancies
- Interventions
- Drug: TislelizumabDrug: PamiparibDrug: SitravatinibDrug: BGB-15025Drug: ZanidatamabDrug: TemozolomideDrug: OciperlimabDrug: BAT1706Drug: FruquintinibDrug: BGB-A445Drug: SurzebiclimabDrug: LenvatinibDrug: LBL-007
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT04164199
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
Early Phase 1
Completed
- Conditions
- Squamous Cell Carcinoma, Head And NeckSquamous Cell Carcinoma MouthSquamous Cell Carcinoma of the Oral Cavity
- Interventions
- Drug: SitravatinibBiological: Nivolumab
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 10
- Registration Number
- NCT03575598
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath